Sanofi (France)
Parent Company
174/180 Avenue de France
Paris
Cedex
75013
France
Tel: 33-1-53-77-4000
Website: http://www.sanofi-synthelabo.fr/
2156 articles about Sanofi (France)
-
Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
7/28/2023
Vaccines up 9.1% due to strong PPH vaccines sales in Rest of World region and COVID vaccine supply in Europe.
-
Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
7/28/2023
Paris, July28, 2023. Sanofi announces it has entered into a definitive agreement to acquire ownership of Qunol®, a U.S.-based, market-leading brand in health & wellness.
-
Press release: Online availability of Sanofi’s half-year financial report for 2023
7/28/2023
Sanofi announces that its half-year financial report for the period ending June 30, 2023 is now available and has been filed with the French market regulator Autorité des marchés financiers and submitted to the U.S. Securities and Exchange Commission under form 6-K.
-
On the heels of a European Union investigation, the UK’s health agency is reviewing safety data for GLP-1 receptor agonists after reports of self-harm and suicidal thoughts.
-
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
7/17/2023
Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, announced an expanded collaboration with Sanofi.
-
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
7/17/2023
The U.S. Food and Drug Administration has approved Sanofi and AstraZeneca’s Beyfortus™ for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
-
The U.S. regulator Monday approved the Beyfortus single-dose monoclonal antibody, developed jointly by the two companies, for the pediatric prevention of respiratory syncytial virus.
-
SK bioscience-Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate
6/30/2023
SK bioscience announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, 'GBP410', evaluating its safety and immunogenicity.
-
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
6/29/2023
Sanofi is hosting a Vaccines Investor Event dedicated to its pipeline with key members of its leadership team.
-
BioMed X Institute Starts Its First Research Project With Sanofi on Artificial Intelligence for Drug Development
6/29/2023
BioMed X, a German independent research institute, announces the start of its first research project in collaboration with Sanofi: "Next Generation Virtual Patient Engine for Clinical Translation of Drug Candidates".
-
Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
6/27/2023
The primary endpoint was met in a Phase 2b study of amlitelimab in adults with moderate-to-severe atopic dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical medications are not a recommended treatment approach.
-
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
6/25/2023
Pivotal data from the Phase 3 XTEND-Kids study evaluating ALTUVIIIOTM [Antihemophilic Factor, Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis, a first-in-class, high-sustained factor VIII replacement therapy, in previously treated patients younger than 12 years of age with severe hemophilia A were presented in a late-breaking session at the Annual Meeting of the International Society on Thrombosis and Haemostasis in Montreal, Canada.
-
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes
6/22/2023
Sanofi announced that its Q2 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website:.
-
An International Chamber of Commerce arbitration tribunal has dismissed Boehringer’s attempt to seek indemnification from Sanofi for the ongoing Zantac lawsuits faced by the companies.
-
The FDA’s Antimicrobial Drugs Advisory Committee voted 21–0 that the companies’ respiratory syncytial virus antibody, nirsevimab, has a favorable benefit-risk profile in infants and young children.
-
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
6/8/2023
Innate Pharma SA is pleased to share Sanofi’s news that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.
-
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
6/8/2023
The U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants born during or entering their first RSV season.
-
The FDA has three high-profile events this week, including one target action date and two advisory committee meetings—one to discuss potential traditional approval for Alzheimer’s drug Leqembi.
-
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
6/1/2023
Sanofi launches Action 2023, its global employee shareholder plan, open to around 86,000 employees in 56 countries.
-
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
5/31/2023
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis.